BRAINSTORM CELL THERAPEUTICS (BCLI) Stock Balance Sheet
NASDAQ:BCLI - Nasdaq - US10501E3009 - Common Stock - Currency: USD
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 168.00K | 1.30M | 770.00K | 18.86M | 37.83M | |||
| Marketable Securities | N/A | 0.00 | 2.21M | 3.24M | 4.11M | |||
| Receivables | 40.00K | 51.00K | 90.00K | 90.00K | 300.00K | |||
| Other Current Assets | 156.00K | 548.00K | 30.00K | 1.10M | 1.00M | |||
| Total Current Assets | 364.00K | 1.90M | 3.11M | 23.28M | 43.24M | |||
| Non-Current Assets | ||||||||
| PPE Net | 1.46M | 2.10M | 5.32M | 5.97M | 7.99M | |||
| Other Non-Current Assets | 203.00K | 207.00K | 20.00K | 30.00K | 30.00K | |||
| Total Non-Current Assets | 1.66M | 2.31M | 5.34M | 6.00M | 8.02M | |||
| TOTAL ASSETS | 2.02M | 4.21M | 8.45M | 29.28M | 51.26M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 1.44M | 1.84M | 1.51M | 1.54M | 3.92M | |||
| Accounts Payable | 4.60M | 4.95M | 6.22M | 3.70M | 5.42M | |||
| Other Current Liabilities | 1.04M | 1.00M | 1.07M | 1.07M | 1.90M | |||
| Total Current Liabilities | 7.08M | 7.80M | 8.80M | 6.32M | 11.23M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 1.00M | 1.27M | 2.67M | 3.62M | 4.56M | |||
| Total Non-Current Liabilities | 1.00M | 1.27M | 2.67M | 3.62M | 4.57M | |||
| TOTAL LIABILITIES | 8.08M | 9.07M | 11.47M | 9.94M | 15.80M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -223.66M | -215.01M | -197.82M | -173.54M | -149.09M | |||
| Additional Paid In Capital | 217.71M | 210.26M | 194.91M | 192.99M | 184.66M | |||
| Common Shares | 14.00K | 13.00K | 10.00K | 10.00K | 10.00K | |||
| Treasury Stock | -116.00K | -116.00K | -120.00K | -120.00K | -120.00K | |||
| Other Shareholders' Equity | N/A | N/A | N/A | N/A | N/A | |||
| Shares Outstanding | 5.31M | 4.03M | 36.69M | 36.40M | 35.16M | |||
| Tangible Book Value per Share | -1.14 | -1.20 | -0.08 | 0.53 | 1.01 | |||
| Total Shareholders' Equity | -6.06M | -4.86M | -3.02M | 19.34M | 35.46M | |||
| TOTAL LIABILITIES AND EQUITY | 2.02M | 4.21M | 8.45M | 29.28M | 51.26M | |||
| Statistics | ||||||||
| Current Ratio | 0.05 | 0.24 | 0.35 | 3.68 | 3.85 | |||
| Return On Assets (ROA) | -702.62% | -408.56% | -287.34% | -83.54% | -62.06% | |||
| Return On Equity (ROE) | N/A | N/A | N/A | -126.47% | -89.71% | |||
All data in USD , ROIC based on taxRate of 0.21